A PILOT-STUDY OF LOW-DOSE ARA-C, INTERFERON-ALPHA AND CIS-RETINOIC ACID (AIR) COMBINATION THERAPY FOR POOR RISK PATIENTS WITH ACUTE MYELOID-LEUKEMIA

被引：1

作者：

LIM, SH

MARCUS, RE

BAGLIN, TP

机构：

[1] Department of Haematology, Addenbrooke's Hospital, Cambridge, CB2 2QQ, Hills Road

来源：

LEUKEMIA & LYMPHOMA | 1991年 / 5卷 / 5-6期

关键词：

AML; POOR RISK; DIFFERENTIATING AGENTS; INTERFERON-ALPHA; CIS-RETINOIC ACID;

D O I：

10.3109/10428199109067627

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

20 adult patients with acute myeloid leukaemia who were considered not suitable for or resistant to conventional chemotherapy were entered into a pilot study of low dose ARA-C, Interferon-alpha and cis-retinoic acid (AIR) combination therapy. The overall response rate was 35%, with 4/20 patients achieving complete remission and 3/20 partial remission. There was also favourable duration of survival among the responders. AIR therapy was well tolerated and was given on an out-patient basis. Hospital admission was minimum during the period of treatment. Most patients however required out-patient support of blood and platelet transfusion. These results indicate that AIR therapy may be beneficial in a selected group of poor risk patients with AML. Further evaluation is needed to identify parameters predictive of response. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：341 / 345

页数：5

共 18 条

[1]

Champlin R., Jacobs A., Gale R.P., Elashoff R., Boccia R., Foon K.A., Zighelboim J., Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy, Lancet, 1, pp. 894-896, (1984)

[2]

Gale R.P., Foon K.A., Cline M.J., Zighelboim J., Intensive chemotherapy for acute myelogenous leukemia, Ann. Intern. Med, 94, pp. 753-757, (1981)

[3]

Crentzig U., Ritter J., Riehm H., Langermann H.J., Henze G., Kabisch H., Niethammer D., Jungens H., Stotlman B., Lasson U., Kaufmann U., Loffer H., Schellong G., Improved treatment results in childhood acute myelogenous leukemia. A report of the German Cooperative Study AML-BFM: 78, Blood, 65, pp. 298-304, (1985)

[4]

Glucksberg H., Cheever M.A., Farewell V.T., Fefer A., Sale G.E., Thomas E.D., High dose combination chemotherapy for acute nonlymphoblastic leukemia in adults, Cancer, 48, pp. 1073-1081, (1981)

[5]

Rees J.K.H., Gray R.G., Swirsky D., Hayhoe F.G.J., Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial, Lancet, 2, pp. 1236-1241, (1986)

[6]

Yates J., Glidewell O., Wiernick P., Cooper M.R., Steinberg D., Dosik H., Levy R., Hoagland C., Henry P., Gottlieb A., Cornell C., Berenberg H., Hutchinson J.L., Raich P., Nissen N., Ellison R.R., Frelick R., James G.W., Falkson G., Silver R.T., Hauroni F., Green M., Henderson E., Leone L., Holland J.F., Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB Study, Blood, 60, pp. 454-462, (1982)

[7]

Kahn S.B., Bogg C.B., Mazza J.J., Bennett J.M., Bonner H., Glick J.H., Full-dose versus attenuated dose daunorubicin, cytosine arabinoside and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly, J. Clin. Oncol, 2, pp. 865-871, (1984)

[8]

Koeffler H.P., Induction of differentation of human acute myelogenous leukemia cells: Therapeutic implications, Blood, 62, pp. 709-721, (1983)

[9]

Collins S.J., Ruscetti F.W., Gallagher R.E., Gallo R.C., Terminal differentiation of human promyelocytic leukemia cells induced by dimethylsulfoxide and other polar compounds, Proc. Natl. Acad. Sci. USA, 75, pp. 2458-2462, (1978)

[10]

Castaigne S., Daniel M.T., Tilley H., Herait P., Degos L., Does treatment with ARA-C in low dosage change differentiation of leukemia cells, Blood, 62, pp. 85-86, (1983)

← 1 2 →